Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aquestive Therapeutics, Inc. - Common Stock
(NQ:
AQST
)
3.840
-0.090 (-2.29%)
Streaming Delayed Price
Updated: 2:28 PM EDT, Mar 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aquestive Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
Today 8:45 EDT
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
March 22, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
March 20, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
March 19, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Aquestive Therapeutics Inc (NASDAQ:AQST) Reports Mixed Q4 2025 Results and Anaphylm Regulatory Update
↗
March 04, 2026
Via
Chartmill
AQST CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026
March 18, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: Levi & Korsinsky
March 17, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
March 17, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
AQST UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026
March 14, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
March 13, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
AQUESTIVE THERAPEUTICS, INC. (AQST) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
March 12, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Rosen Law Firm Urges Aquestive Therapeutics, Inc. (NASDAQ: AQST) Stockholders to Contact the Firm for Information About Their Rights
March 10, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims CEO Allegedly Misrepresented Company Prospects: Levi & Korsinsky
March 10, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
March 10, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
March 09, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQUESTIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. and Encourages Investors to Contact the Firm
March 06, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
March 06, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Launches Investigation into Aquestive Therapeutics
March 06, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
Investor Notice: Robbins LLP Informs Investors of the Aquestive Therapeutics, Inc. Class Action Lawsuit
March 05, 2026
From
Robbins LLP
Via
Business Wire
Aquestive (AQST) Q4 2025 Earnings Call Transcript
↗
March 05, 2026
Aquestive (AQST) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Lawsuit
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 04, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQST SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
March 03, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
February 26, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
February 25, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
February 24, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 23, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting
February 20, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
February 19, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer
February 18, 2026
From
Aquestive Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today